Efficacy and safety of stereotactic body radiation therapy in treatment of patients with unresectable cholangiocarcinoma
10.3969/j.issn.1001-5256.2023.11.021
- VernacularTitle:无法手术切除的胆管细胞癌经体部立体定向放射治疗的效果及安全性分析
- Author:
Xiaofang ZHAO
1
;
Aimin ZHANG
2
;
Wengang LI
2
;
Jing SUN
2
;
Xiaoyun CHANG
2
;
Tao ZHANG
2
;
Weiping HE
2
;
Xuezhang DUAN
1
Author Information
1. Chinese PLA Medical College， Beijing 100039， China
2. Department of Oncology and Radiotherapy， The Fifth Medical Center of Chinese PLA General Hospital， Beijing 100039， China
- Publication Type:Journal Article
- Keywords:
Cholangiocarcinoma;
Radiosurgery;
Treatment Outcome
- From:
Journal of Clinical Hepatology
2023;39(11):2657-2662
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the survival and adverse reactions of patients with unresectable cholangiocarcinoma after stereotactic body radiation therapy （SBRT）. MethodsA total of 27 patients with unresectable solitary cholangiocarcinoma without metastasis who underwent SBRT in The Fifth Medical Center of Chinese PLA General Hospital from February 2012 to July 2020 were enrolled. The prescribed dose to planning target volume was 42-60 Gy in 5-8 fractions， with 5-11 Gy/fraction. Among these patients， five patients were also treated with chemotherapy and transcatheter arterial chemoembolization. The 6-， 12-， 18-， and 24-month overall survival （OS） rates， progression-free survival （PFS） rates， and local control （LC） rates were used as the assessment indices for treatment outcome； Common Terminology Criteria for Adverse Events v.4.03 was used to evaluate adverse reactions； the Kaplan-Meier method was used to calculate OS， PFS， and LC rates. ResultsThe median follow-up time was 17 months. For all 27 patients， the 6-， 12-， 18-， and 24-month OS rates were 100%， 88%， 57.5%， and 47.9%， respectively； the 6-， 12-， 18-， and 24-month PFS rates were 74.1%， 58.6%， 47.9%， and 35.9%， respectively； the 6-， 12-， 18-， and 24-month LC rates were 96.3%， 91.9%， 84.8%， and 76.4%， respectively. No grade 3 or above toxic reactions were observed. Five patients were diagnosed with radiation-induced liver injury， but there was no death due to radiation-induced liver injury. ConclusionSBRT is safe and effective in the treatment of unresectable cholangiocarcinoma， with relatively high survival rate， PFS rate， and LC rate and low toxicity， and therefore， SBRT can be used as an alternative treatment method for patients with cholangiocarcinoma who are not candidates for surgery.
